HALOZYME THERAPEUTICS, INC.
HALO · XNASCIK 1159036fmd_0WM2YQD4PQ0XQXV7RRWW09Y4KBManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 147 | 317 | 152 | 196 | 268 | 443 | 660 | 829 | 1,015 | 1,397 |
| Cost of revenue | 33 | 31 | 10 | 46 | 43 | 81 | 139 | 192 | 159 | 229 |
| Net interest income | – | – | – | – | – | – | – | – | – | – |
| Gross profit | 113 | 285 | 142 | 150 | 224 | 362 | 521 | 637 | 856 | 1,168 |
| Research and development | 151 | 151 | 150 | 141 | 34 | 36 | 67 | 76 | 79 | 81 |
| Selling, general and administrative | 46 | 54 | 61 | 77 | 46 | 50 | 144 | 149 | 154 | 207 |
| Operating income | (83) | 81 | (69) | (68) | 144 | 276 | 268 | 338 | 551 | 469 |
| Interest expense | 20 | 22 | 18 | 12 | 20 | 8 | 17 | 19 | 18 | 18 |
| Other non-operating income (expense) | 1 | 3 | 8 | 7 | 5 | 1 | 1 | 16 | 24 | 21 |
| Income before taxes | (102) | 62 | (80) | (72) | 129 | 249 | 249 | 348 | 557 | 467 |
| Income tax expense | 1 | (1) | 1 | (0) | 0 | (154) | 47 | 67 | 113 | 150 |
| Net income from continuing operations | (103) | 63 | (80) | (72) | 129 | 403 | 202 | 282 | 444 | 317 |
| Net income | (103) | 63 | (80) | (72) | 129 | 403 | 202 | 282 | 444 | 317 |